Страна: Тайван
Език: китайски
Източник: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
REPAGLINIDE
台灣諾和諾德藥品股份有限公司 台北市敦化南路二段216號7樓-1 (23528693)
A10BX02
錠劑
REPAGLINIDE (6820601100) MG
鋁箔盒裝
製 劑
須由醫師處方使用
NOVO NORDISK A/S NOVO ALLE, DK 2880 BAGSVAERD, DENMARK DK
repaglinide
第2型糖尿病(NIDDM)無法經由飲食控制、減重及加強運動等方法,達成良好控制者。
註銷日期: 2017/03/20; 註銷理由: 自請註銷; 有效日期: 2019/10/19; 英文品名: NOVONORM 2MG TABLETS
已註銷
1999-10-19
Code: 100% Direction Length: Max. 25 mm (100%) Code end Regulatory Operations Insert size: 210x297-003 Current: 4.0 Blister COLOUR: PMS 280C 8-1765-00-008-1 NOVONORM® 0.5 MG TABLETS 1 MG TABLETS 2 MG TABLETS Repaglinide QUALITATIVE AND QUANTITATIVE COMPOSITION NovoNorm® contains repaglinide as the active ingredient. The other ingredients are listed in_ List of excipients._ The 0.5 mg tablet is white, round and convex, engraved with Novo Nordisk logo (Apis bull). The 1 mg tablet is yellow, round and convex, engraved with Novo Nordisk logo (Apis bull). The 2 mg tablet is peach-coloured, round and convex, engraved with Novo Nordisk logo (Apis bull). PHARMACOTHERAPEUTIC GROUP Other blood glucose lowering drugs, excl. insulin. MANUFACTURER Novo Nordisk A/S Novo Allé DK-2880 Bagsværd, Denmark THERAPEUTIC INDICATIONS Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin or thiazolidinediones in adults with type 2 diabetes mellitus who are not satisfactorily controlled on repaglinide, metformin or thiazolidinediones alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals. POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Repaglinide is given preprandially and is titrated individually to optimise glycaemic control. In addition to self- monitoring by the patient of blood and/or urinary glucose, the patient’s blood glucose should be monitored periodically by the physician to determine the minimum effective dose for the patient. Glycosylated haemoglobin levels are also of value in monitoring the patient’s response to therapy. Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum level (i.e. primary failure) and to detect loss of adequate blood glucose-lowering response after an initial period of effectiveness (i.e. secondary failure) Прочетете целия документ